LYEL:NASDAQLyell Immunopharma, Inc. Analysis
Data as of 2026-05-20 - not real-time
$16.97
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Lyell Immunopharma (LYEL) is trading at $16.97, well below its 20‑day ($19.86), 50‑day ($21.12) and 200‑day ($20.42) moving averages, signaling a continued downtrend. The RSI of 32 suggests the stock is oversold, while a bearish MACD histogram (‑0.38) reinforces short‑term weakness. Despite this, volume is increasing and the price sits just above a key support level near $15.49, offering a modest technical floor.
Fundamentally, the company posts negative earnings (trailing EPS ‑13.62), a massive price‑to‑sales multiple (>12,700x), and a high beta of 1.92, indicating amplified market swings. Cash of $254 M offsets $39 M of debt, but operating cash flow is deeply negative and revenue has collapsed by 71% YoY. Analyst consensus remains a “Buy” with a median price target of $41.50, implying a potential upside of over 119% and the market sentiment is in the “Extreme Greed” zone (FGI 89.8).
Fundamentally, the company posts negative earnings (trailing EPS ‑13.62), a massive price‑to‑sales multiple (>12,700x), and a high beta of 1.92, indicating amplified market swings. Cash of $254 M offsets $39 M of debt, but operating cash flow is deeply negative and revenue has collapsed by 71% YoY. Analyst consensus remains a “Buy” with a median price target of $41.50, implying a potential upside of over 119% and the market sentiment is in the “Extreme Greed” zone (FGI 89.8).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Oversold RSI near 32 provides limited upside potential
- Price is just above the $15.49 support level
- Increasing volume may support a short‑term bounce
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Progress of the PiNACLE pivotal CAR‑T trial could unlock significant valuation
- Analyst price targets suggest >100% upside
- Strong cash position relative to modest debt
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Potential market‑changing CAR‑T therapies in both hematologic and solid tumor indications
- Long‑term industry growth in biotech and immunotherapy
- Ability to fund R&D through existing cash reserves
Key Metrics & Analysis
Financial Health
Revenue Growth-71.40%
P/E Ratio-20.2
ROE-80.76%
ROA-29.66%
Debt/Equity14.43
P/B Ratio1.3
Op. Cash Flow$-133796000
Free Cash Flow$-65480876
Industry P/E27.1
Technical Analysis
TrendNeutral
RSI32.5
Support$15.49
Resistance$24.95
MA 20$19.86
MA 50$21.12
MA 200$20.42
MACDBearish
VolumeIncreasing
Fear & Greed Index89.82
Valuation
Target Price$37.17
Upside/Downside119.01%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.92
Volatility67.46%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.